Assessing the economic impact of psychiatric disorders: Where to begin?

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 4, 2001, Pages 641-652

  Greenberg, P E ^a   Leong, S A ^a   Birnbaum, H G ^a  

^a Analysis Group/Economics   (United States)

Author keywords

Cost; Economics; Impact; Outcomes; Pharmacoeconomics; Prevalence; Psychiatric disorders; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADDICTION; AFFECTIVE NEUROSIS; ANXIETY NEUROSIS; CAREGIVER; COMORBIDITY; DEPRESSION; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH SERVICE; HUMAN; MEDICAL EXPERT; MENTAL DISEASE; PHARMACOECONOMICS; PREVALENCE; PROSPECTIVE PAYMENT; PSYCHOSIS; PUBLIC HEALTH; REVIEW; SELF HELP; SOCIAL ASPECT; SOCIETY; SYMPTOM; ECONOMICS;

ECONOMICS, PHARMACEUTICAL; HUMAN; MENTAL DISORDERS; PREVALENCE;

EID: 0035012611     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.4.641     Document Type: Review

References (100)

1. The economic burden of depression in 1990
2. The economic burden of anxiety disorders in the 1990s
3. Economic considerations and formulary management of oral antipsychotics
4. Spending on Mental Health and Substance Abuse Treatment, 1987-1997
5. The design of the Epidemiologic Catchment Area surveys: The control and measurement of error
6. Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United States
7. Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey
8. The economics of women and depression: And employer's perspective
9. Substance dependence and other psychiatric disorders among drug dependent subjects: Race and gender
10. Gender and bipolar illness
11. Age at onset of schizophrenia: Gender differences and influence of temporal socioeconomic change
12. Women and schizophrenia
13. Gender differences in depression: Critical review
14. Gender differences in chronic major and double depression
15. Comorbid Medical Illness in Psychiatric Patients
16. The course, morbidity, and costs of depression
17. Depression: A neglected major illness
18. The socioeconomics of depression
19. A family study of major depressive disorder in a community sample of adolescents
20. Depressive disorders: Treatment patterns and costs of treatment in the private sector of the United States
21. Increasing use of new prescription drugs: A case study
22. The workplace burden of depression: Underlying causes, recent empirical findings, and future Directions
23. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population
24. Health care costs of primary care patients with recognized depression
25. The effects of psychosocial distress and psychological well-being on use of medical services
26. The impact of antidepressant use on social functioning: Reboxetine versus fluoxetine
27. Course of depression for adult outpatients: Results from the Medical Outcomes Study
28. Somatization and psychiatric disorder in the NIMH Epidemiologic Catchment Area Study
29. Costs of Depressive Disorders: A Review
30. Physical symptoms in primary care: Predictors of psychiatric disorders and functional impairment
31. The quality of care for depressive and anxiety disorders in the United States
32. The functioning and well-being of depressed patients: Results from the medical outcomes study
33. Adequacy and duration of antidepressant treatment in primary care
34. Depression in the community: The first pan-European study DEPRES (Depression Research in European Society)
35. The national depressive and manic-depressive association consensus statement on the undertreatment of depression
36. The deliberate misdiagnosis of major depression in primary care
37. Utilization of health and mental health services: Three epidemiological catchment area studies
38. Unrecognized depression in general practice
39. Workplace Burden of Depression: A Case Study in Social Functioning Using Employer Claims Data
40. The enhancement of social functioning as a therapeutic principle in the management of depression
41. Social Consequences of Psychiatric Disorders, I: Educational Attainment
42. Social Consequences of Psychiatric Disorders, II: Teenage Parenthood
43. The Social Consequences of Psychiatric Disorders, III: Probability of Marital Stability
44. Lost human capital from early onset chronic depression
45. The impact of psychiatric disorders on labor market outcomes
46. Clinical issues related to the costs of alcoholism
47. Service utilization and social morbidity, associated with depressive symptoms in the community
48. Depression, disability days, and days lost from work in a prospective epidemiologic survey
49. The impact of psychiatric disorders on work loss days
50. The economic burden of depression
51. The economic impact of depression in a workplace
52. Work and earnings losses due to mental illness: Perspectives from three national surveys
53. Depression and work productivity: The comparative costs of treatment versus nontreatment
54. The role of health risk factors and disease on worker productivity
55. Disability and depression among high utilizers of health care. A longitudinal analysis
56. Health care costs associated with depressive and anxiety disorders in primary care
57. Distressed high utilizers of medical care, DMS-III-R diagnoses and treatment needs
58. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization
59. Effect of primary care treatment of depression on service use by patients with high medical expenditures
60. Major depression in women: A review of the literature
61. The value of mental health care at the system level: The case of treating depression
62. Treatment preferences among depressed primary care patients
63. Fluoxetine: A pharmacoeconomic review of its use in depression
64. Treatments of depression and the functional capacity to work
65. Beyond Symptoms: Social functioning and the new antidepressants
66. Labor productivity effects of prescribed medicines for chronically ill workers
67. The NIMH depression awareness, recognition, and treatment program: Structure, aims, and scientific basis
68. Population-based care of depression: Effective disease management strategies to decrease prevalence
69. Management of major depression in the workplace: Impact on employee work loss
70. Absenteeism among employees treated for depression
71. How can care for depression become more cost-effective?
72. Prescribing selective serotonin reuptake inhibitors for prevention of suicide Br.
73. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability
74. Are SSRIs a cost-effective alternative to tricyclics?
75. Antidepressant pharmacotherapy: Cost comparison of SSRIs and TCAs
76. Is there an economic advantage in the use of SSRIs over TCAs in the treatment of depression?
77. The efficacy of selective serotonin reuptake inhibitors in depression: A meta-analysis of studies against tricyclic antidepressants
78. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs
79. Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data: The Role of Nonrandom Selection and Skewed Data
80. Initial antidepressant choice in primary care
81. Patterns of antidepressant use and their relation to costs of care
82. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline
83. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: A multivariate analysis
84. Cost implications of initial antidepressant selection in primary care
85. Acute medical costs of fluoxetine versus tricyclic antidepressants: A prospective multicentre study of antidepressant drug overdoses
86. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization
87. Course and costs of depression treatment with fluoxetine, paroxetine, and sertraline
88. Parozetine: A pharmacoeconomic evaluation of its use in depression
89. Sertraline: A pharmacoeconomic evaluation of its use in depression
90. Fluoxetine: A pharmacoeconomic evaluation of its use in depression
91. Health economic evaluations of antidepressants: A review
92. Cost-effectiveness of newer antidepressants compared with tricyclic antidepressants in managed care settings
93. Impact of illness and its Treatment on Workplace Costs: Regulatory and Measurement Issues